Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57


Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.

Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, Chen HZ, Reeser JW, Wing MR, Miya J, Samorodnitsky E, Smith AM, Dao T, Martin DM, Ciombor KK, Hays J, Freud AG, Roychowdhury S.

Mol Cancer Ther. 2020 Mar;19(3):847-857. doi: 10.1158/1535-7163.MCT-19-0631. Epub 2020 Jan 7.


EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia.

Bill M, Pathmanathan A, Karunasiri M, Shen C, Burke MH, Ranganathan P, Papaioannou D, Zitzer NC, Snyder K, LaRocco A, Walker AE, Brannan ZJ, Nalin AP, Freud AG, Dikov MM, Zhang X, Bloomfield CD, Garzon R, Dorrance AM.

Clin Cancer Res. 2020 Feb 1;26(3):669-678. doi: 10.1158/1078-0432.CCR-19-2479. Epub 2019 Oct 31.


True Detective: Unraveling Group 1 Innate Lymphocyte Heterogeneity.

Riggan L, Freud AG, O'Sullivan TE.

Trends Immunol. 2019 Oct;40(10):909-921. doi: 10.1016/ Epub 2019 Sep 6. Review.


Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.

Krook MA, Bonneville R, Chen HZ, Reeser JW, Wing MR, Martin DM, Smith AM, Dao T, Samorodnitsky E, Paruchuri A, Miya J, Baker KR, Yu L, Timmers C, Dittmar K, Freud AG, Allenby P, Roychowdhury S.

Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4). pii: a004002. doi: 10.1101/mcs.a004002. Print 2019 Aug.


Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.

Krook MA, Barker H, Chen HZ, Reeser JW, Wing MR, Martin D, Smith AM, Dao T, Bonneville R, Samorodnitsky E, Miya J, Freud AG, Monk JP, Clinton SK, Roychowdhury S.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):624-632. doi: 10.1038/s41391-019-0145-2. Epub 2019 May 1.


Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy.

Chen HZ, Bonneville R, Yu L, Wing MR, Reeser JW, Krook MA, Miya J, Samorodnitsky E, Smith A, Martin D, Dao T, Guo Q, Liebner D, Freud AG, Allenby P, Roychowdhury S.

Oncotarget. 2019 Jan 8;10(3):277-288. doi: 10.18632/oncotarget.26352. eCollection 2019 Jan 8.


Cellular pathways in the development of human and murine innate lymphoid cells.

Scoville SD, Freud AG, Caligiuri MA.

Curr Opin Immunol. 2019 Feb;56:100-106. doi: 10.1016/j.coi.2018.11.003. Epub 2018 Dec 19. Review.


The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells.

Wang Y, Zhang Y, Yi P, Dong W, Nalin AP, Zhang J, Zhu Z, Chen L, Benson DM, Mundy-Bosse BL, Freud AG, Caligiuri MA, Yu J.

Nat Immunol. 2019 Jan;20(1):10-17. doi: 10.1038/s41590-018-0265-1. Epub 2018 Dec 10.


CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway.

Chen L, Youssef Y, Robinson C, Ernst GF, Carson MY, Young KA, Scoville SD, Zhang X, Harris R, Sekhri P, Mansour AG, Chan WK, Nalin AP, Mao HC, Hughes T, Mace EM, Pan Y, Rustagi N, Chatterjee SS, Gunaratne PH, Behbehani GK, Mundy-Bosse BL, Caligiuri MA, Freud AG.

Immunity. 2018 Sep 18;49(3):464-476.e4. doi: 10.1016/j.immuni.2018.08.010. Epub 2018 Sep 4.


SMAD4 promotes TGF-β-independent NK cell homeostasis and maturation and antitumor immunity.

Wang Y, Chu J, Yi P, Dong W, Saultz J, Wang Y, Wang H, Scoville S, Zhang J, Wu LC, Deng Y, He X, Mundy-Bosse B, Freud AG, Wang LS, Caligiuri MA, Yu J.

J Clin Invest. 2018 Nov 1;128(11):5123-5136. doi: 10.1172/JCI121227. Epub 2018 Oct 15.


Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function.

Scoville SD, Nalin AP, Chen L, Chen L, Zhang MH, McConnell K, Beceiro Casas S, Ernst G, Traboulsi AA, Hashi N, Williams M, Zhang X, Hughes T, Mishra A, Benson DM, Saultz JN, Yu J, Freud AG, Caligiuri MA, Mundy-Bosse BL.

Blood. 2018 Oct 25;132(17):1792-1804. doi: 10.1182/blood-2018-03-838474. Epub 2018 Aug 29.


MicroRNA regulation of natural killer cell development and function in leukemia.

Saultz JN, Freud AG, Mundy-Bosse BL.

Mol Immunol. 2019 Nov;115:12-20. doi: 10.1016/j.molimm.2018.07.022. Epub 2018 Aug 9. Review.


Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.

Mundy-Bosse B, Denlinger N, McLaughlin E, Chakravarti N, Hwang S, Chen L, Mao HC, Kline D, Youssef Y, Kohnken R, Lee DA, Lozanski G, Freud AG, Porcu P, William B, Caligiuri MA, Mishra A.

Blood Adv. 2018 Aug 14;2(15):1818-1827. doi: 10.1182/bloodadvances.2018020388. No abstract available.


Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development.

Victor AR, Weigel C, Scoville SD, Chan WK, Chatman K, Nemer MM, Mao C, Young KA, Zhang J, Yu J, Freud AG, Oakes CC, Caligiuri MA.

J Immunol. 2018 Jan 15;200(2):565-572. doi: 10.4049/jimmunol.1701128. Epub 2017 Dec 11.


The Broad Spectrum of Human Natural Killer Cell Diversity.

Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA.

Immunity. 2017 Nov 21;47(5):820-833. doi: 10.1016/j.immuni.2017.10.008. Review.


Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.

Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, Jaiswal S, Kinzie M, Waikhom S, Freud AG, Zhou XP, Chen W, Bhatt D, Roychowdhury S.

Oncotarget. 2017 Sep 1;8(44):75822-75833. doi: 10.18632/oncotarget.20616. eCollection 2017 Sep 29.


Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.

Andritsos LA, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD, Freud AG, Blachly JS, Lucas DM, Lozanski G, Jones JA, Williams K, Oakes C, Jones D, Grever MR.

Leuk Lymphoma. 2018 Apr;59(4):1008-1011. doi: 10.1080/10428194.2017.1365853. Epub 2017 Sep 18. No abstract available.


IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-κB.

Victor AR, Nalin AP, Dong W, McClory S, Wei M, Mao C, Kladney RD, Youssef Y, Chan WK, Briercheck EL, Hughes T, Scoville SD, Pitarresi JR, Chen C, Manz S, Wu LC, Zhang J, Ostrowski MC, Freud AG, Leone GW, Caligiuri MA, Yu J.

J Immunol. 2017 Oct 1;199(7):2333-2342. doi: 10.4049/jimmunol.1601554. Epub 2017 Aug 25.


Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.

Reeser JW, Martin D, Miya J, Kautto EA, Lyon E, Zhu E, Wing MR, Smith A, Reeder M, Samorodnitsky E, Parks H, Naik KR, Gozgit J, Nowacki N, Davies KD, Varella-Garcia M, Yu L, Freud AG, Coleman J, Aisner DL, Roychowdhury S.

J Mol Diagn. 2017 Sep;19(5):682-696. doi: 10.1016/j.jmoldx.2017.05.006. Epub 2017 Aug 9.


Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

Haverkos BM, Coleman C, Gru AA, Pan Z, Brammer J, Rochford R, Mishra A, Oakes CC, Baiocchi RA, Freud AG, Porcu P.

Discov Med. 2017 Mar;23(126):189-199. Review.


Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells.

Scoville SD, Freud AG, Caligiuri MA.

Front Immunol. 2017 Mar 27;8:360. doi: 10.3389/fimmu.2017.00360. eCollection 2017.


Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas.

Haverkos BM, Huang Y, Gru A, Pancholi P, Freud AG, Mishra A, Ruppert AS, Baiocchi RA, Porcu P.

Int J Cancer. 2017 Apr 15;140(8):1899-1906. doi: 10.1002/ijc.30566.


Biallelic mutations in IRF8 impair human NK cell maturation and function.

Mace EM, Bigley V, Gunesch JT, Chinn IK, Angelo LS, Care MA, Maisuria S, Keller MD, Togi S, Watkin LB, LaRosa DF, Jhangiani SN, Muzny DM, Stray-Pedersen A, Coban Akdemir Z, Smith JB, Hernández-Sanabria M, Le DT, Hogg GD, Cao TN, Freud AG, Szymanski EP, Savic S, Collin M, Cant AJ, Gibbs RA, Holland SM, Caligiuri MA, Ozato K, Paust S, Doody GM, Lupski JR, Orange JS.

J Clin Invest. 2017 Jan 3;127(1):306-320. doi: 10.1172/JCI86276. Epub 2016 Nov 28.


Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M, Otto B, Barrionuevo C, Baiocchi RA, Rochford R, Porcu P.

Curr Hematol Malig Rep. 2016 Dec;11(6):514-527. doi: 10.1007/s11899-016-0355-9. Review.


MicroRNA-29b mediates altered innate immune development in acute leukemia.

Mundy-Bosse BL, Scoville SD, Chen L, McConnell K, Mao HC, Ahmed EH, Zorko N, Harvey S, Cole J, Zhang X, Costinean S, Croce CM, Larkin K, Byrd JC, Vasu S, Blum W, Yu J, Freud AG, Caligiuri MA.

J Clin Invest. 2016 Dec 1;126(12):4404-4416. doi: 10.1172/JCI85413. Epub 2016 Oct 24.


Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma.

Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S181-S190.e4. doi: 10.1016/j.clml.2016.02.014.


NKp80 Defines a Critical Step during Human Natural Killer Cell Development.

Freud AG, Keller KA, Scoville SD, Mundy-Bosse BL, Cheng S, Youssef Y, Hughes T, Zhang X, Mo X, Porcu P, Baiocchi RA, Yu J, Carson WE 3rd, Caligiuri MA.

Cell Rep. 2016 Jul 12;16(2):379-391. doi: 10.1016/j.celrep.2016.05.095. Epub 2016 Jun 30.


A Progenitor Cell Expressing Transcription Factor RORγt Generates All Human Innate Lymphoid Cell Subsets.

Scoville SD, Mundy-Bosse BL, Zhang MH, Chen L, Zhang X, Keller KA, Hughes T, Chen L, Cheng S, Bergin SM, Mao HC, McClory S, Yu J, Carson WE 3rd, Caligiuri MA, Freud AG.

Immunity. 2016 May 17;44(5):1140-50. doi: 10.1016/j.immuni.2016.04.007. Epub 2016 May 10.


Myeloid Cell Nuclear Differentiation Antigen (MNDA) Expression Distinguishes Extramedullary Presentations of Myeloid Leukemia From Blastic Plasmacytoid Dendritic Cell Neoplasm.

Johnson RC, Kim J, Natkunam Y, Sundram U, Freud AG, Gammon B, Cascio MJ.

Am J Surg Pathol. 2016 Apr;40(4):502-9. doi: 10.1097/PAS.0000000000000595.


The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Gru AA, Haverkos BH, Freud AG, Hastings J, Nowacki NB, Barrionuevo C, Vigil CE, Rochford R, Natkunam Y, Baiocchi RA, Porcu P.

Curr Hematol Malig Rep. 2015 Dec;10(4):456-67. doi: 10.1007/s11899-015-0292-z. Review.


Rapid Column-Free Enrichment of Mononuclear Cells from Solid Tissues.

Scoville SD, Keller KA, Cheng S, Zhang M, Zhang X, Caligiuri MA, Freud AG.

Sci Rep. 2015 Jul 30;5:12490. doi: 10.1038/srep12490.


Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function.

Deng Y, Kerdiles Y, Chu J, Yuan S, Wang Y, Chen X, Mao H, Zhang L, Zhang J, Hughes T, Deng Y, Zhang Q, Wang F, Zou X, Liu CG, Freud AG, Li X, Caligiuri MA, Vivier E, Yu J.

Immunity. 2015 Mar 17;42(3):457-70. doi: 10.1016/j.immuni.2015.02.006. Epub 2015 Mar 10.


The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells.

Hughes T, Briercheck EL, Freud AG, Trotta R, McClory S, Scoville SD, Keller K, Deng Y, Cole J, Harrison N, Mao C, Zhang J, Benson DM, Yu J, Caligiuri MA.

Cell Rep. 2014 Jul 10;8(1):150-62. doi: 10.1016/j.celrep.2014.05.042. Epub 2014 Jun 19.


Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma.

Metcalf RA, Monabati A, Vyas M, Roncador G, Gualco G, Bacchi CE, Younes SF, Natkunam Y, Freud AG.

Hum Pathol. 2014 Aug;45(8):1730-6. doi: 10.1016/j.humpath.2014.04.004. Epub 2014 Apr 24.


Human natural killer cell development in secondary lymphoid tissues.

Freud AG, Yu J, Caligiuri MA.

Semin Immunol. 2014 Apr;26(2):132-7. doi: 10.1016/j.smim.2014.02.008. Epub 2014 Mar 21. Review.


Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia.

Freud AG, Zhao S, Wei S, Gitana GM, Molina-Kirsch HF, Atwater SK, Natkunam Y.

Am J Clin Pathol. 2013 Dec;140(6):853-66. doi: 10.1309/AJCPWGG69MCZOWMM.


Location and cellular stages of natural killer cell development.

Yu J, Freud AG, Caligiuri MA.

Trends Immunol. 2013 Dec;34(12):573-82. doi: 10.1016/ Epub 2013 Sep 19. Review.


CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.

Anderson MW, Zhao S, Freud AG, Czerwinski DK, Kohrt H, Alizadeh AA, Houot R, Azambuja D, Biasoli I, Morais JC, Spector N, Molina-Kirsch HF, Warnke RA, Levy R, Natkunam Y.

Am J Pathol. 2012 Sep;181(3):795-803. doi: 10.1016/j.ajpath.2012.05.015.


Evidence for a stepwise program of extrathymic T cell development within the human tonsil.

McClory S, Hughes T, Freud AG, Briercheck EL, Martin C, Trimboli AJ, Yu J, Zhang X, Leone G, Nuovo G, Caligiuri MA.

J Clin Invest. 2012 Apr;122(4):1403-15. doi: 10.1172/JCI46125. Epub 2012 Mar 1.


PRDM1/Blimp-1 controls effector cytokine production in human NK cells.

Smith MA, Maurin M, Cho HI, Becknell B, Freud AG, Yu J, Wei S, Djeu J, Celis E, Caligiuri MA, Wright KL.

J Immunol. 2010 Nov 15;185(10):6058-67. doi: 10.4049/jimmunol.1001682. Epub 2010 Oct 13.


Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue.

Hughes T, Becknell B, Freud AG, McClory S, Briercheck E, Yu J, Mao C, Giovenzana C, Nuovo G, Wei L, Zhang X, Gavrilin MA, Wewers MD, Caligiuri MA.

Immunity. 2010 Jun 25;32(6):803-14. doi: 10.1016/j.immuni.2010.06.007.


In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis.

Guimond M, Freud AG, Mao HC, Yu J, Blaser BW, Leong JW, Vandeusen JB, Dorrance A, Zhang J, Mackall CL, Caligiuri MA.

J Immunol. 2010 Mar 15;184(6):2769-75. doi: 10.4049/jimmunol.0900685. Epub 2010 Feb 8.


Purification of human NK cell developmental intermediates from lymph nodes and tonsils.

Freud AG, Caligiuri MA.

Methods Mol Biol. 2010;612:1-14. doi: 10.1007/978-1-60761-362-6_1.


Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22.

Hughes T, Becknell B, McClory S, Briercheck E, Freud AG, Zhang X, Mao H, Nuovo G, Yu J, Caligiuri MA.

Blood. 2009 Apr 23;113(17):4008-10. doi: 10.1182/blood-2008-12-192443. Epub 2009 Feb 24.


Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells.

Benson DM Jr, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA.

Blood. 2009 Mar 19;113(12):2706-14. doi: 10.1182/blood-2008-05-159285. Epub 2008 Dec 5.


Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells.

Becknell B, Hughes TL, Freud AG, Blaser BW, Yu J, Trotta R, Mao HC, Caligiuri de Jesús ML, Alghothani M, Benson DM Jr, Lehman A, Jarjoura D, Perrotti D, Bates MD, Caligiuri MA.

Blood. 2007 Mar 15;109(6):2481-7. Epub 2006 Nov 16.


Human natural killer cell development.

Freud AG, Caligiuri MA.

Immunol Rev. 2006 Dec;214:56-72. Review.


A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.

Shah MH, Freud AG, Benson DM Jr, Ferkitich AK, Dezube BJ, Bernstein ZP, Caligiuri MA.

Clin Cancer Res. 2006 Jul 1;12(13):3993-6.


Evidence for discrete stages of human natural killer cell differentiation in vivo.

Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA.

J Exp Med. 2006 Apr 17;203(4):1033-43. Epub 2006 Apr 10.


IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease.

Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, Bergdall V, Kusewitt D, Baiocchi RA, Caligiuri MA.

Blood. 2005 Oct 1;106(7):2433-5. Epub 2005 Jun 23.

Supplemental Content

Loading ...
Support Center